Low concentrations of vorinostat decrease EB1 expression in GBM cells and affect microtubule dynamics, cell survival...

Area of Science:

• Neuro-oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Glioblastoma multiforme (GBM) is an aggressive brain tumor with high mortality.
• Histone deacetylase inhibitors (HDACi) show promise but lack selectivity, causing side effects.
• EB1 overexpression is a known marker of poor prognosis in GBM.

Purpose of the Study:

• To investigate the novel anticancer properties and mechanisms of low-dose vorinostat in GBM cells.
• To explore vorinostat's effects on microtubule dynamics and EB1 expression in GBM.
• To assess the therapeutic potential of low-dose vorinostat for GBM, particularly in EB1-overexpressing tumors.

Main Methods:

• Treatment of various GBM cells with low concentrations of vorinostat.
• Analysis of tubulin acetylation and detyrosination.
• Assessment of the impact on microtubule plus-end stabilizing caps (EB proteins) and microtubule dynamics.
• Evaluation of EB1 expression levels in response to vorinostat treatment.

Main Results:

• Low-dose vorinostat affects the microtubule cytoskeleton in a non-histone 3 (H3) manner.
• Vorinostat induces tubulin acetylation and detyrosination, impacting microtubule stability.
• The drug suppresses microtubule dynamic instability by affecting EB stabilizing caps.
• A significant decrease in EB1 expression was observed in GBM cells treated with vorinostat.

Conclusions:

• Low-dose vorinostat, potentially selective for HDAC6, exhibits novel anticancer mechanisms in GBM.
• Vorinostat's ability to decrease EB1 expression is a significant finding for GBM therapy.
• This approach may offer a more targeted and less toxic therapeutic option for GBM patients, especially those with EB1 overexpression.
• Further clinical trials are warranted to validate these findings.